Batterjee joined the company, assuming his current role in November 2014. Batterjee Pharma manufactures and markets generic pharmaceutical products and also serves as a contract development and manufacturing organization (CDMO) with a portfolio of over 50 products, with another 50 expected within 18 months. In Q1 2025, it posted $63 million in revenue and $129 million in assets, reflecting a 40% year-on-year revenue increase and a 53% rise in exports. In 2025, the company concluded six new manufacturing agreements with six firms, for about 20 pharmaceutical products. It also has signed four licensing-in agreements covering biosimilars, inhalers and ophthalmic for a range of 14 products to be commercialized in Saudi Arabia and MEA.